Accessibility Menu
PaxMedica logo

PaxMedica(OTC) PXMD

Market Cap$88.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year+600%
1 Month+40%
$0.00
+40.00%
+0.00Today
PaxMedica last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-31
PaxMedica stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+40%USD 0.002026-07-23
1 month+40%USD 0.002026-07-01
3 month+40%USD 0.002026-05-01
Year to date+600%USD 0.002025-12-31
1 year+600%USD 0.002025-07-30
3 year-99.99%USD 10.842023-08-01
Since inception-100%USD 83.472022-08-26

PaxMedica Financials at a Glance

Market Cap

$88.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$17.66M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

585

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.02

Estimated Earnings Date

Sep 2, 2026

PXMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PaxMedica

PaxMedica develops medicines for people with hard-to-treat brain disorders. Its main products aim to help those with autism and rare diseases. The company focuses on new drug approaches for conditions with few treatment options.

Brainy Business: What PaxMedica Sells

  • PAX-101 (Intravenous Suramin): Experimental drug for autism, chronic fatigue, long COVID, and sleeping sickness; 0% of revenue (pre-commercial).
  • PAX-102 (Intranasal Suramin): Early-stage drug for brain-related disorders; 0% of revenue (pre-commercial).
  • New Chemical Entities: Research on new drugs targeting purine receptors; 0% of revenue (pre-commercial).
  • Distribution Agreement: Exclusive U.S. rights for PAX-101 with Vox Nova, pending approval; 0% of revenue.

Plot Twists: Growth and Expansion Moves

  • Signed exclusive U.S. distribution deal with Vox Nova for PAX-101 in 2023.
  • Completed key FDA meetings in 2023 and 2024 to advance PAX-101 for sleeping sickness.
  • Raised $0.8 million in September 2024 through a warrant exchange.
  • Changed name from Purinix Pharmaceuticals to PaxMedica in April 2020.
  • Delisted from Nasdaq in May 2024; now trades on OTC Pink Market.

What Makes PaxMedica Stand Out

PaxMedica targets rare brain disorders with few treatment options. It uses a unique drug approach called anti-purinergic therapy, aiming to block certain cell signals. The company partners with academic groups and relies on third-party manufacturers for its research and development.

Five Things You Need to Know

  • No product revenue reported for Q2 2024, Q2 2023, or Q2 2022.
  • Operating loss was $3.0 million in Q2 2024, an increase of 10.7% from Q2 2023.
  • Cash balance was $0.3 million as of June 30, 2024, down from $4.7 million at year-end 2023.
  • Research and development spending focused on sleeping sickness ($1.2M) and autism ($0.7M) in first half 2024.
  • Delisting from Nasdaq in May 2024 limits access to capital markets.

Bottom Line

PaxMedica is a small biotech focused on new treatments for difficult brain disorders. The company faces funding and regulatory hurdles as it works to bring its first products to market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7

CEO

Howard J. Weisman

Website

www.paxmedica.com

Headquarters

Tarrytown, NY 10591, US

PXMD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-1046.98%

Return on Capital

-476.95%

Return on Assets

-321.98%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$88.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

126.26M

Volume

585

Avg. Volume

1.41K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$15.44M

EBITDA

-$17.66M

Operating Cash Flow

-$9.32M

Capital Expenditure

$0.00

Free Cash Flow

-$9.32M

Cash & ST Invst.

$324.49K

Total Debt

$0.00

PaxMedica Performance Analysis

PaxMedica annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
PaxMedica sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30N/A
Q42023-12-31N/A
Q12024-03-31N/A
Q22024-06-30N/A
PaxMedica annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -14.76N/A
20222022-12-31USD -20.9141.6%
20232023-12-31USD -11.00-47.4%
PaxMedica sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30-28.4%
Q42023-12-3184.6%
Q12024-03-3137.5%
Q22024-06-3022.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$88.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$14.73K

N/A

Employees

6

N/A

Net Income

-$3.00M

+14.0%

EBITDA

-$3.00M

+13.9%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$324.49K

-89.4%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-3.22%

N/A

Return on Invested Capital

-4.16%

N/A

Free Cash Flow

-$1.30M

+54.1%

Operating Cash Flow

-$1.30M

+54.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VAXXVaxxinity, Inc.
$0.00+0.00%
QBIOQ BioMed Inc.
$0.00-0.00%
HLUNHEALTHeUNIVERSE, Inc.
$0.00+0.00%
TRVNTrevena, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About PXMD

What is the current price of PaxMedica?

PaxMedica is trading at $0.00 per share.

What is the 52-week range for PaxMedica?

Over the past 52 weeks, PaxMedica has traded between $0.00 and $0.02.

How much debt does PaxMedica have?

As of the most recent reporting period, PaxMedica reported total debt of $0.00.

How much cash does PaxMedica have on hand?

PaxMedica reported $444.86K in cash and cash equivalents in its most recent financial results.

What is PaxMedica’s dividend yield?

PaxMedica does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services